Patents by Inventor Phillip Dan Cook

Phillip Dan Cook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5777092
    Abstract: Oligonucleotide-mimicking macromolecules that have improved nuclease resistance are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligonucleotides with three or four atom linking groups provide unique oligonucleotide-mimicking macromolecules that are useful in regulating RNA expression and in therapeutics. Methods of synthesis and use also are disclosed.
    Type: Grant
    Filed: February 4, 1997
    Date of Patent: July 7, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Yogesh Shantilal Sanghvi
  • Patent number: 5760202
    Abstract: Improved processes for the synthesis of 2'-O-substituted pyrimidine nucleosides are provided. The processes feature alkylation of a 2,2'-anhydropyrimidine nucleoside or a 2S,2'-anhydropyrimidine nucleoside with a weak nucleophile in the presence of a Lewis acid.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 2, 1998
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Robert H. Springer, Kelly G. Sprankle, Bruce S. Ross
  • Patent number: 5731438
    Abstract: Compositions comprising novel di-nitrogen heterocycle compounds containing N-(aminoalkyl) and/or N-(amidoalkyl) groups are prepared. The compounds of the present invention are useful as antibacterial and other pharmaceutical agents and as intermediates for preparation of other pharmaceutical agents. In addition, compounds of the present invention are useful as research reagents.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: March 24, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Andrew M. Kawasaki, Pei Pei Kung
  • Patent number: 5719271
    Abstract: Covalent cross-linkages for two oligonucleotide strands or for first and second regions of a single oligonucleotide strand connect sugar moieties of nucleotides on the respective strands or the regions of the single strand. The cross-linkages are connected to at least one strand or region via a space-spanning group. The cross-linkage also can be connected to the other strand or other region via a space-spanning group or via an abasic site located on the other strand or other region.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: February 17, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Muthiah Manoharan, Thomas Bruice
  • Patent number: 5717083
    Abstract: Compounds are provided having structure (I), wherein the L groups are backbone segments, the Y and T groups are functional groups for interacting with target molecules of interest, the X groups are oxygen or sulfur and the E groups are H, conjugate groups or intermediate groups used during the synthesis of the compounds and wherein the compounds are prepared using H phosphonate type chemistry wherein the functional groups are added during an oxidation step or during a coupling step.
    Type: Grant
    Filed: August 19, 1996
    Date of Patent: February 10, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Oscar Acevedo, Normand Hebert
  • Patent number: 5700922
    Abstract: Macromolecules are provided that have increased nuclease resistance, increasing binding affinity to a complementary strand, and that activate RNase H enzyme. The macromolecules have the structure PNA-DNA-PNA where the DNA portion is composed of subunits of 2'-deoxy-erythro-pentofuranosyl nucleotides and the PNA portions are composed of subunits of peptide nucleic acids. Such macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to therapeutics.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: December 23, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Phillip Dan Cook
  • Patent number: 5698391
    Abstract: Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled oligomers are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.
    Type: Grant
    Filed: December 16, 1994
    Date of Patent: December 16, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, David J. Ecker, Jacqueline Wyatt, Thomas W. Bruice, Kevin Anderson, Ronnie Hanecak, Timothy Vickers, Peter Davis, Susan M. Freier, Yogesh S. Sanghvi, Vickie Brown-Driver
  • Patent number: 5688941
    Abstract: Tetrahydrofuranyl compounds are provided that are functionalized to include pendant conjugate groups, and which are useful in diagnostic assays and as research reagents. Novel intermediates for the synthesis of the compounds are also provided.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: November 18, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Kelly Teng
  • Patent number: 5681941
    Abstract: This invention is directed to novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents--agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The compounds of the invention may also be used for cross-linking oligonucleotides. Oligonucleotides are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.
    Type: Grant
    Filed: February 1, 1994
    Date of Patent: October 28, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Muthiah Manoharan, Kanda S. Ramasamy
  • Patent number: 5677437
    Abstract: Oligonucleotide-mimicking macromolecules that have improved nuclease resistance are provided. Replacement of the normal phosphorodiester inter-sugar linkages found in natural oligonucleotides with four atom linking groups provide unique compounds that are useful in regulating RNA expression and in therapeutics. Methods of synthesis and use also are disclosed.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: October 14, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kelly Teng, Yogesh S. Sanghvi, Phillip Dan Cook
  • Patent number: 5670633
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least two of the 2'-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of HIV, herpes virus, papillomavirus and other infections is provided.
    Type: Grant
    Filed: March 5, 1992
    Date of Patent: September 23, 1997
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Andrew Mamoro Kawasaki
  • Patent number: 5661134
    Abstract: Sequence-specific phosphorothioate oligonucleotides comprising nucleoside units which are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages are provided. Such sequence-specific phosphorothioate oligonucleotides having substantially chirally pure intersugar linkages are prepared by enzymatic or chemical synthesis. They are especially well suited as diagnostics, therapeutics, and research reagents in diseases mediated by Ha-ras or Ki-ras.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 26, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Glenn Hoke
  • Patent number: 5654284
    Abstract: Sequence-specific phosphorothioate oligonucleotides comprising nucleoside units which are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages are provided. Such sequence-specific phosphorothioate oligonucleotides having substantially chirally pure intersugar linkages are prepared by enzymatic or chemical synthesis.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 5, 1997
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Phillip Dan Cook, Glenn Hoke